The US FDA has accepted a Biologics License Application (BLA) from Sandoz for a proposed denosumab biosimilar. ...more
The U.S. Patent Trials & Appeals Board (Board) recently issued an Order granting Celltrion’s motion to submit supplemental information in its IPR (2022-00578) against U.S. Pat. No. 8,580,264, owned by Chugai Seiyaku...more